回生口服液联合一线化疗方案对晚期非小细胞肺癌患者血清VEGF，IL-6和MMP-9水平的影响
| 作者: |
1吴明君,
1王向东,
1陈瑜,
1杨林东,
1梁玉河
1 宝鸡市人民医院胸心外科，陕西 宝鸡 721000 |
| 通讯: |
梁玉河
Email: 397099565@qq.com |
| DOI: | 10.3978/j.issn.2095-6959.2017.12.016 |
| 基金: | 国家自然科学基金青年项目(81602597)。 |
摘要
目的：探讨回生口服液联合一线化疗方案对中晚期非小细胞肺癌(non-small cell lung cancer，NSCLC)的治疗效果及对患者血清VEGF，IL-6，MMP-9水平的影响。方法：收集95例2011年5月至2014年6月在我院治疗的中晚期NSCLC患者并回顾其治疗方案，将入组患者随机分为两组：观察组与对照组。观察组接受一线化疗方案联合回生口服液，对照组仅接受一线化疗方案。以21 d为1个周期，治疗4个周期后，比较两组的近期疗效、血清VEGF，IL-6，MMP-9水平的变化以及不良反应情况。结果：观察组总有效率为72.92%，对照组总有效率为53.19%，组间临床疗效相比，差异有统计学意义(PVEGF<0.001，PIL-6=0.022，PMMP-9<0.001)。治疗前两组血清VEGF，IL-6，MMP-9水平相近，差异均无统计学意义(PVEGF=0.072，PIL-6=0.054，PMMP-9=0.121)；治疗后两组血清VEGF，IL-6以及MMP-9水平显著降低(观察组：PVEGF<0.001，PIL-6=0.016，PMMP-9<0.001；对照组：PVEGF=0.003，PIL-6=0.011，PMMP-9=0.005)，且观察组下降水平较对照组更明显(PVEGF=0.003，PIL-6=0.027，PMMP-9=0.021)。两组不良反应主要为消化道反应及骨髓抑制，观察组在白细胞减少的发生率方面明显较对照组低(P=0.013)。结论：回生口服液联合一线化疗方案可有效降低晚期NSCLC患者的血清VEGF，IL-6和MMP-9水平，临床受益率较高，且耐受性好，值得推广。
关键词：
非小细胞肺癌；回生口服液；血管内皮生长因子；白细胞介素-6；基质金属蛋白酶-9
Effects of Huisheng oral liquid combined with first-line chemotherapy on serum levels of VEGF, IL-6 and MMP-9 in advanced non-small cell lung cancer patients
CorrespondingAuthor: LIANG Yuhe Email: 397099565@qq.com
DOI: 10.3978/j.issn.2095-6959.2017.12.016
Foundation: This work was supported by the Youth Project of National Natural Science Foundation, China (81602597).
Abstract
Objective: To investigate the clinical effect of Huisheng oral liquid combined with first-line chemotherapy on serum levels of VEGF, IL-6 and MMP-9 in advanced non-small cell lung cancer patients. Methods: We selected 95 patients with advanced non-small cell lung cancer treated in our hospital from May 2011 to June 2014. According to different treatment methods, the patients were divided into two groups: observation group and control group. The observation group received Huisheng oral liquid combined with first-line chemotherapy, the control group just received first-line chemotherapy. After four courses of treatment, the short-term effect and the serum VEGF, IL-6, MMP-9 levels in two groups were compared. Results: The total effective rate of observation group was 72.92%, it is 53.19% for control group, there had the significant difference in clinical efficacy between the two groups (PVEGF<0.001, PIL-6=0.022, PMMP-9<0.001). The serum VEGF, IL-6, MMP-9 levels of two groups were similar before treatment, there were no significant differences (PVEGF=0.072, PIL-6=0.054, PMMP-9=0.121). After the treatment, in disease control group, serum levels of VEGF, IL-6, MMP-9 were significantly decreased (PVEGF<0.001, PIL-6=0.016, PMMP-9<0.001); and the observation group were lower than in the control group, the differences were statistically significant (PVEGF=0.003, PIL-6=0.011, PMMP-9=0.005). But in the disease progression group, the serum VEGF, IL-6, MMP-9 levels increased and the difference was statistically significant (PVEGF=0.003, PIL-6=0.027, PMMP-9=0.021). The main side effects of the two groups were digestive tract reaction and bone marrow suppression, and the incidence of WBC decrease in the observation group was significantly lower than that in the control group (P=0.013). Conclusion: The combine of Huisheng oral liquid and first-line chemotherapy can monitor the serum levels of VEGF, IL-6 and MMP-9 in advanced non-small cell lung cancer patients. This method can achieve better results.
Keywords：
non-small cell lung cancer; Huisheng oral liquid; vascular endothelial growth factor; interleukin-6; matrix metalloproteinase-9